Your #1 Podcast on Cannabis News

Podcast: Special Ed. | From Anecdote to Evidence: Data for Advanced Access | Releaf & Dr Anne Katrin Schlag

In this special edition of the Business of Cannabis Podcast, we go From Anecdote to Evidence with Dr Anne Katrin Schlag, Head of Research at Drug Science, and Graham Woodward, Chief Operating Officer at Releaf.

 

In this special edition of the Business of Cannabis Podcast, we go From Anecdote to Evidence with Dr Anne Katrin Schlag, Head of Research at Drug Science, and Graham Woodward, Chief Operating Officer at Releaf.

Together, they explore how the UK can move from anecdotal patient stories to robust, real-world evidence — and why this shift is vital for expanding safe, trusted access to cannabis-based medicines.

They unpack how clinics like Releaf are investing in quality-of-life surveys and data-driven patient care, what this means for regulators like NICE, and whether more solid evidence can finally open doors with the BMA, Royal College and wider healthcare system.

For anyone interested in how data and patient outcomes can unlock the next stage of UK medical cannabis, this is a conversation not to miss.

You can watch the other episodes here. 

Twitter: www.twitter.com/bofc_global / www.twitter.com/bofc_europe
LinkedIn: www.linkedin.com/company/businessofcannabis
Instagram: www.instagram.com/businessofcannabis
Facebook: www.facebook.com/bofcmedia
Apple: http://bofc.me/applepod
Podcasts Online: https://bofc.me/bofclive

Topics#Dr Anne Katrin SchlagDrug ScienceGraham WoodwardpodcastReleaf

Ben Stevens

Ben is the editor of Business of Cannabis. Since 2021, he has researched, written, and published the vast majority of the outlet’s content, delivering agenda-setting journalism on regulation, business strategy, and policy across Europe.

More from Ben

Spotted an error, or have a tip? Contact the newsroom.

Up next · Your #1 Podcast on Cannabis News

Business of Cannabis: Podcast | The Broken Promise of UK Medical Cannabis – Releaf x Fieldfisher

Ben Stevens · 27 May 2025

More